Certara Announces Pricing of Public Offering of Common Stock

Rhea-AI Summary

Certara, a leader in biosimulation, announced the pricing of an underwritten public offering of 10 million shares at $31.00 each, solely by existing stockholders. The underwriters have a 30-day option to purchase an additional 1.5 million shares. Certara will not receive proceeds from this offering, which is expected to close on November 22, 2021. This offering is managed by Jefferies, Morgan Stanley, and BofA Securities, among others. A registration statement has been declared effective by the SEC.

Positive

• None.

Negative

• Potential dilution of existing shares due to the offering.

PRINCETON, N.J., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the pricing of its underwritten public offering of 10 million shares of its common stock by certain existing stockholders (the “selling stockholders”) at a price to the public of $31.00 per share. Additionally, the selling stockholders have granted the underwriters a 30-day option to purchase up to 1.5 million additional shares of common stock. Certara is not selling any shares and will not receive any proceeds from the sale of shares in the offering by the selling stockholders. The offering is expected to close on or about November 22, 2021, subject to customary closing conditions.

The offering is being made through an underwriting group led by Jefferies, Morgan Stanley and BofA Securities, who are acting as lead joint book-running managers, and Barclays, William Blair, Baird and Capital One Securities, who are acting as joint book-running managers.

A registration statement on Form S-1, including a prospectus, relating to these securities has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering may be made only by means of a prospectus. Copies of the preliminary prospectus may be obtained by contacting: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022, by telephone at (877) 547-6340 or by email at Prospectus_Department@jefferies.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014 or by email at prospectus@morganstanley.com; or BofA Securities, Inc., NC1-004-03-43, Attention: Prospectus Department, 200 North College Street, 3rd Floor, Charlotte, NC 29255 or by email at dg.prospectus_requests@bofa.com.

About Certara

Certara accelerates medicines using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.

Investor Relations Contact:
David Deuchler
Gilmartin Group
ir@certara.com

Media Contact:
Daniel Yunger
Kekst CNC
daniel.yunger@kekstcnc.com

FAQ

What is the price of Certara's public offering of shares?

The price of Certara's public offering is $31.00 per share.

How many shares is Certara offering for sale?

Certara is offering 10 million shares of its common stock.

Who is managing Certara's public offering?

The offering is managed by Jefferies, Morgan Stanley, and BofA Securities, among others.

When is the expected closing date for the offering?

The offering is expected to close on November 22, 2021.

Will Certara receive any proceeds from the offering?

No, Certara will not receive any proceeds from the sale of shares by the selling stockholders.